Gene profiling predicts treatment response in refractory RA: study
UK researchers say their findings represent a 'paradigm shift' in precision medicine for affected patients
Genetic profiling of synovial biopsies predicts lack of therapeutic response to biologics in patients with rheumatoid arthritis better than a model using only tissue pathology or clinical factors, a study shows.
UK researchers say their findings could pave the way for routine use of gene expression models for optimal selection of rituximab and tocilizumab treatment in this clinical setting.
“We believe this study is a paradigm shift in precision medicine in RA [rheumatoid arthritis],” said study authors and
